Scinai Immunotherapeutics Ltd (SCNI) Fair Value & Analysis
Healthcare · US · Market cap $1.6M
Scinai Immunotherapeutics Ltd
SCNI · US
Risks
Fair value as of: Aug 24, 2026
From 1 valuation models · updated today
Share price +36.1% over the past month.
Below-average quality, and trading another 251% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($1.33). The favourable scenario is already priced in.
- Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.6630 to $1.33) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 24, 2026.
How to read this chart
60‑month range $2.28 – $3,440 · fair‑value band $0.6630 – $1.33 · the $3.13 price screens above the $0.8925 fair value. Dashed = 300-day average. As of Aug 24, 2026.
Analysis
Scinai Immunotherapeutics Ltd (SCNI) currently trades at $3.13, while our model-based Fair Value estimate is $0.8925, implying the stock looks roughly 71.5% overvalued today. The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $1.2M. Revenue declined 16.6% year over year. It earns a return on equity of -29.2%. The stock trades on a trailing P/E of 0.2 (as of Jun 23, 2026). Fundamentals as of Aug 24, 2026
Our scenario range runs from $0.6630 (bear case) to $1.33 (bull case); at $3.13, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high. For context, the median of 10 Healthcare peers we cover trades at -60% fair-value upside, at -71%, SCNI screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when SCNI reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 14
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally.
Full company description
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Scinai Immunotherapeutics Ltd reported revenue of $1.3M in FY2025 versus $0 in FY2021. Reported net income was −$8.3M in FY2025.
SCNI screens 71% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 637 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| argenx SE ARGX | €877.60 | €292.84 | -67% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | -77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | -60% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | -69% |
| Moderna, Inc MRNA | $63.67 | $12.77 | -80% |
| BioNTech SE 22UA | €80.60 | €52.92 | -34% |
Compare Scinai Immunotherapeutics Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Scinai Immunotherapeutics Ltd (SCNI) overvalued or undervalued?
What is the fair value of SCNI?
What is the quality score of SCNI?
What is the revenue of Scinai Immunotherapeutics Ltd (SCNI)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Scinai Immunotherapeutics Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.